Reviva provides corporate and program updates and highlights key upcoming milestones

– schizophrenia late-stage clinical program advances with positive topline phase 3 data, successful ongoing enrollment in open label extension (ole) trial, and positive drug-drug interaction data supporting a differentiated profile for once-daily brilaroxazine –
RVPH Ratings Summary
RVPH Quant Ranking